Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Lenvatinib is the most common multitarget receptor tyrosine kinase inhibitor for the treatment of advanced hepatocellular carcinoma (HCC). Acquired resistance to lenvatinib is one of the major factors leading to the failure of HCC treatment, but the underlying mechanism has not been fully characterized. We established lenvatinib-resistant cell lines, cell-derived xenografts (CDXs) and patient-derived xenografts (PDXs) and obtained lenvatinib-resistant HCC tumor tissues for further study. We found that ubiquitin-specific protease 14 (USP14) was significantly increased in lenvatinib-resistant HCC cells and tumors. Silencing USP14 significantly attenuated lenvatinib resistance and . Mechanistically, USP14 directly interacts with and stabilizes calcium- and integrin-binding protein 1 (CIB1) by reversing K48-linked proteolytic ubiquitination at K24, thus facilitating the P21-activated kinase 1 (PAK1)-ERK1/2 signaling axis. Moreover, adeno-associated virus 9 mediated transduction of CIB1 promoted lenvatinib resistance in PDXs, whereas CIB1 knockdown resensitized the response of PDXs to lenvatinib. These findings provide new insights into the role of CIB1/PAK1-ERK1/2 signaling in lenvatinib resistance in HCC. Targeting CIB1 and its pathways may be a novel pharmaceutical intervention for the treatment of lenvatinib-resistant HCC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11234209 | PMC |
| http://dx.doi.org/10.7150/ijbs.96031 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antrocinol-Mediated Downregulation of ATG5 Induces Autophagy-Dependent Cell Death and Activates the Unfolded Protein Response Through PERK/CHOP Signaling in Lenvatinib-Resistant Hepatocellular Carcinoma Cells.
Eur J Pharmacol
September 2025
Department of Emergency Medicine, Shuang-Ho Hospital, Taipei Medical University, New Taipei City, Taiwan; Department of Emergency Medicine, School of Medicine, Taipei Medical University, Taipei, Taiwan. Electronic address:
Background: This study seeks to provide preclinical evidence demonstrating the potential of Antrocinol, a derivative of antrocin derived from the active compound of Antrodia cinnamomea, as a promising small-molecule drug candidate for overcoming drug-resistant hepatocellular carcinoma (HCC).
Methods: We developed Lenvatinib-resistant Huh-7 and HepG cell lines (Huh-7/LR, HepG2/LR) to evaluate their viability and apoptotic response to Antrocinol. Autophagy-dependent cell death was assessed in Huh-7/LR cells using Z-VAD-FMK and shATG5 transfection.
Pembrolizumab combined with lenvatinib and metronomic cyclophosphamide in platinum-resistant ovarian cancer: a case report of durable clinical response.
Front Oncol
August 2025
Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
Most patients with ovarian cancer experience disease recurrence or progression, and ultimately progress to platinum resistance. Standard treatments for platinum-resistant ovarian cancer (PROC) include non-platinum chemotherapy, targeted agents, and immunotherapy. Despite recent advances in individualized management of PROC, median progression-free survival remains limited.
View Article and Find Full Text PDFAssociation of triglyceride-glucose index with long-term prognosis in advanced hepatocellular carcinoma patients receiving immunotherapy and targeted therapy.
World J Gastroenterol
August 2025
Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, Jiangsu Province, China.
Background: Primary liver cancer, particularly hepatocellular carcinoma (HCC), ranks as the sixth most prevalent cancer globally and the third major cause of cancer-associated mortality. Despite the available immunotherapies and combined immunotherapy and targeted therapy, the prognosis for many patients remains dismal. Accurately identifying the appropriate patient cohorts is crucial for improving treatment outcomes.
View Article and Find Full Text PDFCopper ionophore complex ES-Cu synergizes with quercetin to target FDX1, promote cuproptosis, and reverse lenvatinib resistance in hepatocellular carcinoma cells.
J Adv Res
September 2025
Shanghai Key Laboratory of Molecular Imaging, Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health Sciences, Shanghai 201318, China; School of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, China. Electronic address:
Introduction: Lenvatinib resistance remains a major challenge in hepatocellular carcinoma (HCC) treatment, highlighting the need for novel therapeutic strategies. Cuproptosis, a copper-dependent form of cell death, has been increasingly implicated in cancer progression. Quercetin, a naturally occurring bioactive flavonol known to modulate mitochondrial metabolism and multiple oncogenic signaling pathways, has emerged as a potential sensitizer.
View Article and Find Full Text PDFA phase 1/1b study of lenvatinib and cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Oral Oncol
September 2025
Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Background: Despite overexpression of EGFR in head/neck squamous cell carcinoma (HNSCC), cetuximab monotherapy has limited benefit. Lenvatinib is a multi-targeted receptor tyrosine kinase inhibitor with activity against FGFRs1-4, involved in resistance to EGFR inhibition. We evaluated lenvatinib in combination with cetuximab in recurrent/metastatic (R/M) HNSCC.
View Article and Find Full Text PDF